Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)

scientific article published on 01 June 1991

Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1600-0404.1991.TB03962.X
P698PubMed publication ID1887756

P2093author name stringK Abe
Y Nishikawa
M Kameyama
H Fujimura
S Yorifuji
N Hirono
N Nishitani
T Mezaki
P433issue6
P921main subjectlactic acidosisQ1500373
mitochondrial myopathyQ6881881
P304page(s)356-359
P577publication date1991-06-01
P1433published inActa Neurologica ScandinavicaQ4676732
P1476titleMarked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)
P478volume83

Reverse relations

cites work (P2860)
Q42928969Age-related deficiencies in complex I endogenous substrate availability and reserve capacity of complex IV in cortical neuron electron transport
Q36225925Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects
Q38114007Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications
Q28375775Coenzyme Q10 does not prevent oral dyskinesias induced by long-term haloperidol treatment of rats
Q73614293Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases
Q74579034Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry
Q48173034Evidence of altered energy metabolism in autistic children
Q41272025Mitochondrial encephalopathies
Q91728645Neuroprotective effect of solanesol against 3-nitropropionic acid-induced Huntington's disease-like behavioral, biochemical, and cellular alterations: Restoration of coenzyme-Q10-mediated mitochondrial dysfunction
Q34218646Nutritional cofactor treatment in mitochondrial disorders
Q43585280Subcutaneous microdialysis in mitochondrial cytopathy
Q36492305The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options
Q41180888The treatment of congenital lactic acidoses
Q57086168The use of lymphocytes to screen for oxidative phosphorylation disorders
Q45305438Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Q35718544Therapeutic effects of coenzyme Q10 in neurodegenerative diseases
Q24200432Treatment for mitochondrial disorders
Q24244543Treatment for mitochondrial disorders
Q40898218Treatment of mitochondrial disease
Q80348054[Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects?]

Search more.